Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer.

Future oncology (London, England) - 1 May 2026

Kim Jinyong, Ahn Myung-Ju

Abstract excerpt

HER2 mutations define a distinct molecular subset of non-small cell lung cancer (NSCLC) associated with poor outcomes and limited benefit from conventional systemic therapies. Zongertinib is a next-generation, HER2-selective irreversible tyrosine kinase inhibitor (TKI) designed to spare wild-type EGFR and improve tolerability. Zongertinib has demonstrated clinically meaningful systemic and intracranial activity...

Topics

Join the communities discussing this publication.

Acrylamides
Brain Neoplasms
Carcinoma, Non-Small-Cell Lung
Erb-b2 Receptor Tyrosine Kinases
Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 42017474
DOI: 10.1080/14796694.2026.2658641
PMCID: PMC13154961

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer.PMID 42017474Read ↗

Evaluation of zongertinib for the treatment of metastatic non-squamous non-small cell lung cancer with HER2 TKD activating mutation.Semantic proximity Read ↗

The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review.Semantic proximity Read ↗

The development of Zongertinib for HER2-mutant NSCLCSemantic proximity Read ↗

Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape.Semantic proximity Read ↗

First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Zongertinib: First Approval.Semantic proximity Read ↗

Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung CancerSemantic proximity Read ↗

Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.Semantic proximity Read ↗

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report.Semantic proximity Read ↗

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.Semantic proximity Read ↗

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.